Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.
Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.